Welcome to our dedicated page for Venus Concept news (Ticker: VERO), a resource for investors and traders seeking the latest updates and insights on Venus Concept stock.
Venus Concept Inc. (NASDAQ: VERO) is a medical aesthetic technology company whose news flow reflects both its product developments and its capital and strategic actions. The company describes itself as a global medical aesthetic technology leader with a portfolio of minimally invasive and non-invasive systems for body, face, skin and hair restoration applications. Its updates often highlight device platforms such as Venus Versa, Venus Legacy, Venus Bliss, Venus Viva, Venus Epileve, AI.ME and, more recently, the next-generation Venus NOVA platform.
On this news page, readers can follow VERO news related to quarterly financial results, regulatory milestones, financing transactions and strategic portfolio moves. Recent press releases have covered second and third quarter financial results, including revenue by region and product category, gross profit trends, operating expenses and operating loss. Management commentary in these releases discusses the performance of energy-based device revenues, the impact of macroeconomic conditions on capital equipment sales, and the company’s efforts in cost containment and operational streamlining.
Venus Concept’s news also includes regulatory and product announcements, such as FDA 510(k) clearance for Venus NOVA, a multi-application platform for non-invasive body and skin treatments that integrates Adaptive EMS, proprietary (MP)² technology and Advanced VariPulse. In addition, the company reports on capital structure and financing events, including registered direct offerings of common stock, private placements of warrants, bridge loan drawdowns and debt-to-equity exchanges of subordinated convertible notes into Series Y Preferred Stock.
Another recurring theme in VERO news is the company’s strategic initiatives, notably the definitive agreement to sell its Venus Hair business, which includes NeoGraft and the ARTAS iX Robotic Hair Restoration system, to MHG Co. Ltd. Investors and observers can use this page to monitor how these developments evolve over time, from transaction announcements and court-related updates to subsequent financial disclosures.
Venus Concept (NASDAQ: VERO) has received a medical device license from Health Canada to market the Venus Fiore Feminine Health System. This follows the CE Mark received in March 2020. The limited launch in Canada and the EU is expected in Q3 2021.
The Venus Fiore system uniquely addresses feminine health issues, providing three non-surgical treatments: internal vaginal, labia tightening, and mons pubis skin tightening. Designed for post-menopausal women, it aims to enhance sexual quality of life and improve physical appearance.
Venus Concept, a leader in medical aesthetic technology, will participate in the Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 2:30 p.m. ET. An audio webcast of the presentation will be available on the company’s investor relations website, with an archive for later access.
The company operates a subscription-based business model, offering a wide range of devices for minimally invasive and non-invasive aesthetic treatments and hair restoration systems worldwide.
Venus Concept (NASDAQ: VERO) will announce its second quarter financial results for fiscal year 2021 on August 13, 2021, before market open. A conference call to discuss these results will occur at 8:00 a.m. ET the same day, with a Q&A session to follow. Interested parties may join by dialing 877-407-2991, or view the live webcast on the company's investor relations site. Venus Concept is recognized for its wide range of minimally invasive and non-invasive aesthetic technologies across over 60 countries, supporting a subscription-based sales model in North America.
Venus Concept (NASDAQ: VERO) reported a 56% increase in total revenue for Q1 2021, reaching $22.6 million compared to $14.5 million in Q1 2020. The company's gross margin improved to 67.4% from 64.0%, while the GAAP operating loss significantly decreased to $6.8 million from $43.6 million year-over-year. Adjusted EBITDA loss decreased 63% to $5.0 million. The company revised its 2021 revenue guidance to $100 million to $105 million, an anticipated growth of 28% to 35%.
Venus Concept (NASDAQ: VERO) announced its financial results for Q1 fiscal year 2021 will be released on May 17, 2021, after market close. A conference call is scheduled for the same day at 5:00 PM ET to discuss these results, with participation details provided for both domestic and international callers. The call will also be available via a live webcast and archived for later access. Venus Concept is known for its innovative medical aesthetic technologies, operating in over 60 countries with a subscription-based sales model.
Venus Concept (NASDAQ: VERO) reported Q4 2020 revenue of $25.8 million, down 19% YoY from $31.9 million, impacted by COVID-19. However, it marked a 25% increase from Q3 2020's $20.7 million. The operating loss decreased by 42% YoY to $10.3 million, with a net loss of $15.0 million, improving from $22.7 million in Q4 2019. Adjusted EBITDA loss was $2.4 million, compared to $11.5 million the previous year. For 2021, guidance suggests revenue growth of 26% to 32%, assuming no significant COVID-19 resurgence. Cash stood at $34.4 million as of December 31, 2020.
Venus Concept (NASDAQ: VERO) announced the signing of Venus Williams as the brand ambassador for its Venus Bliss™ product line. CEO Dom Serafino expressed enthusiasm about this partnership, stating Williams represents the company's vision and values. Williams, a highly accomplished athlete and entrepreneur, has a positive public image that aligns with the brand. Venus Concept is a leader in medical aesthetic technology, offering a range of minimally invasive and non-invasive products across over 60 countries.
Venus Concept (NASDA: VERO) announced its participation in major investor conferences in March 2021. The Oppenheimer 31st Annual Healthcare Conference will take place virtually from March 16-18, with management presenting at 3:10 p.m. ET on March 17. They will also participate in the Maxim Emerging Growth Conference on March 17-18, featuring a panel discussion on March 17 at 2:00 p.m. ET. Audio webcasts of these presentations will be available on their investor relations website.
Venus Concept, a leading global medical aesthetic technology firm, announced its participation in the H.C. Wainwright Annual Global Life Sciences Conference on March 9-10, 2021. The company's management will present virtually, with the presentation available on-demand starting March 9 at 7:00 a.m. Eastern Time. The audio webcast can be accessed on the company’s investor relations website, and an archive will be available post-conference. Venus Concept operates in over 60 countries, offering a broad range of minimally invasive aesthetic technologies and hair restoration systems.
Venus Concept, a leader in medical aesthetic technology, announced its participation in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 17, 2021, at 10:00 a.m. Eastern Time.
The engagement will feature a virtual fireside chat, accessible via an audio webcast on the Company’s investor relations website. Post-event, an archive of the webcast will be available for replay. Venus Concept specializes in minimally invasive aesthetic technologies and has operations in over 60 countries.
FAQ
What is the current stock price of Venus Concept (VERO)?
What is the market cap of Venus Concept (VERO)?
